Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 5/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886176 | 1.00 | GLA (0.39) | GLANR1H3NR1H2KLK7PLA2G10 | |
| SCHEMBL8073190 | 0.78 | NR1H3 (0.36) | NR1H3NR1H2KLK7PLA2G10PLA2G5 | |
| SCHEMBL8886431 | 0.78 | NR1H3 (0.36) | NR1H3NR1H2KLK7PLA2G10PLA2G5 | |
| SCHEMBL28713624 | 0.77 | PTPN1 (0.38) | GLANR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL8065158 | 0.77 | NR1H3 (0.37) | GLANR1H3NR1H2KLK7PLA2G10 | |
| SCHEMBL8886373 | 0.77 | NR1H3 (0.37) | GLANR1H3NR1H2KLK7PLA2G10 | |
| SCHEMBL8065148 | 0.77 | NR1H3 (0.36) | NR1H3NR1H2KLK7PLA2G10PLA2G5 | |
| SCHEMBL24700403 | 0.76 | USP2 (0.39) | GLAUSP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL23522781 | 0.76 | USP2 (0.39) | GLAUSP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL12901412 | 0.76 | USP2 (0.39) | GLAUSP2SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0666844-B1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0812203-A4 | INHIBITORS OF GERANYLGERANYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| EP-0812203-A1 | INHIBITORS OF GERANYLGERANYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5652257-A | ANTICARCINOGENIC | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5576293-A | TETRAPEPTIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5470832-A | Inhibitors of geranylgeranyl-protein transferase | MERCK & CO., INC. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995020396-A1 | INHIBITORS OF GERANYLGERANYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
| WO-1994010138-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | GLA 956/4885NR1H3 390/4885NR1H2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.